HCID 58529663, Verbindung → HCID 58529448, Verbindung
Reaktionsgleichung
[NH2:1][C:2]1[C:7]2=[C:8](Br)[CH:9]=[C:10]([CH:11]3[CH2:16][CH2:15][N:14]([C:17]([O:19][C:20]([CH3:23])([CH3:22])[CH3:21])=[O:18])[CH2:13][CH2:12]3)[N:6]2[N:5]=[CH:4][N:3]=1.[CH2:25]([N:32]1[CH:40]=[C:39]2[C:34]([CH:35]=[C:36](B3OC(C)(C)C(C)(C)O3)[C:37]([F:41])=[CH:38]2)=[N:33]1)[C:26]1[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=1>>[C:20]([O:19][C:17]([N:14]1[CH2:15][CH2:16][CH:11]([C:10]2[N:6]3[C:7]([C:2]([NH2:1])=[N:3][CH:4]=[N:5]3)=[C:8]([C:36]3[C:37]([F:41])=[CH:38][C:39]4[C:34]([CH:35]=3)=[N:33][N:32]([CH2:25][C:26]3[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=3)[CH:40]=4)[CH:9]=2)[CH2:12][CH2:13]1)=[O:18])([CH3:23])([CH3:22])[CH3:21]Komponenten
3
Versuchsvorschrift
To the microwave vial was added tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (250 mg, 0.63 mmol), 2-benzyl-5-fluoro-6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2H-indazole (300 mg, 0.85 mmol, 1.35 eq), and tetrakis(trephenylphosphine)palladium (0) (46 mg, 0.063 mmol, 0.1 eq). Degassed, anhydrous DMF (6.3 mL) was added followed by 2.0M sodium carbonate solution (1.0 mL). The vial was capped and the reaction was irradiated in a microwave reactor at 180° C. for 25 min. The mixture was cooled to rt, diluted with EtOAc and filtered through a pad of Celite® to remove excess palladium. The filtrate was washed with 50% aqueous brine (3×), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by ISCO® (gradient elution 0 to 10% MeOH/DCM) to give the product (309.7 mg, 68%) as an oil. 1H-NMR (300 MHz, CD3OD) 8.35 (s, 1H), 7.84 (s, 1H), 7.63 (d, 1H), 7.56 (d, 1H), 7.38 to 7.31 (m, 5H), 6.59 (s, 1H), 5.65 (s, 2H), 4.23 to 4.17 (m, 2H), 3.48 to 3.39 (m, 1H), 2.95 (broad s, 2H), 2.12 (d, 2H), 1.72 to 1.59 (m, 2H), 1.47 (s, 9H); ES-MS m/z 542.3 [M+H]+, RT (min) 3.10.